Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) in which Arrowhead will receive $825 million on closing, consisting of a $500 million upfront payment and $325 million as an equity investment priced at a 35% premium.</li><li>The agreement includes four clinical stage products (ARO-DUX4, ARO-DM1, ARO-MMP7, ARO-ATXN2), three preclinical programs (ARO-HTT, ARO-ATXN1, ARO-ATXN3), and during the five-year term of the agreement Sarepta can propose up to six new CNS or muscle targets, with Arrowhead responsible for discovery and preclinical development.</li><li>This deal further validates Arrowheads technology and provides capital to fund operations into 2028.</li></ul>

On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) in which Arrowhead will receive $825 million on closing, consisting of a $500 million upfront payment and $325 million as an equity investment priced at a 35% premium.The agreement includes four clinical stage products (ARO-DUX4, ARO-DM1, ARO-MMP7, ARO-ATXN2), three preclinical programs (ARO-HTT, ARO-ATXN1, ARO-ATXN3), and during the five-year term of the agreement Sarepta can propose up to six new CNS or muscle targets, with Arrowhead responsible for discovery and preclinical development.This deal further validates Arrowheads technology and provides capital to fund operations into 2028.

ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing 

<ul><li>On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome (FCS).</li><li>The trial met its primary endpoint and all key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipoprotein C-III (APOC3), and the incidence of acute pancreatitis.</li><li>The data were presented in a late-breaking oral presentation at the European Society of Cardiolog (ESG) Congress 2024 and simultaneously published in The New England Journal of Medicine.</li></ul>

On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome (FCS).The trial met its primary endpoint and all key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipoprotein C-III (APOC3), and the incidence of acute pancreatitis.The data were presented in a late-breaking oral presentation at the European Society of Cardiolog (ESG) Congress 2024 and simultaneously published in The New England Journal of Medicine.

ARWR: PALISADE Phase 3 Results Published in NEJM 

<ul><li>On August 8, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.</li><li> Arrowhead recently presented preclinical data on ARO-INHBE and introduced ARO-ALK7 at its summer seminar on obesity/metabolic disorders.</li><li>We anticipate both programs entering the clinic in 2025.</li></ul>

On August 8, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update. Arrowhead recently presented preclinical data on ARO-INHBE and introduced ARO-ALK7 at its summer seminar on obesity/metabolic disorders.We anticipate both programs entering the clinic in 2025.

ARWR: Two Obesity Assets to Enter the Clinic in 2025 

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul>
<li>Arrowhead Pharmaceuticals recently discussed its fiscal 2024 third-quarter performance and provided updates on its drug pipeline and commercial strategies, suggesting a pivotal phase in its growth trajectory.</li>
<li>As the pharmaceutical company aims to augment its pipeline to include around 20 clinical or marketed products by 2025, it focuses heavily on the development and potential market launch of its flagship product, plozasiran, targeting familial chylomicronemia syndrome (FCS) and other conditions associated with high triglycerides.</li>
<li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li>
</ul>


Arrowhead Pharmaceuticals recently discussed its fiscal 2024 third-quarter performance and provided updates on its drug pipeline and commercial strategies, suggesting a pivotal phase in its growth trajectory.
As the pharmaceutical company aims to augment its pipeline to include around 20 clinical or marketed products by 2025, it focuses heavily on the development and potential market launch of its flagship product, plozasiran, targeting familial chylomicronemia syndrome (FCS) and other conditions associated with high triglycerides.
Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.


Arrowhead Pharmaceuticals: Expanding Clinical Trials & Regulatory Approvals!

<ul>
<li>Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024.</li>
<li>A major focus for the company during this period has been its expanding presence in the cardiometabolic space, where substantial investments have been channeled to advance clinical and pre-commercial activities.</li>
<li>In these endeavors, significant strides were made with plozasiran and zodasiran, their leading drug candidates designed to tackle diseases associated with lipid disorders.</li>
</ul>


Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024.
A major focus for the company during this period has been its expanding presence in the cardiometabolic space, where substantial investments have been channeled to advance clinical and pre-commercial activities.
In these endeavors, significant strides were made with plozasiran and zodasiran, their leading drug candidates designed to tackle diseases associated with lipid disorders.


Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas!

United States

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arrowhead Pharmaceuticals (ARWR US)

ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing

On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics...

Zacks Small Cap Research

ARWR: PALISADE Phase 3 Results Published in NEJM

On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with...

Zacks Small Cap Research

ARWR: Two Obesity Assets to Enter the Clinic in 2025

On August 8, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2024 that ended June...

Zacks Small Cap Research

Arrowhead Pharmaceuticals: Expanding Clinical Trials & Regulatory Approvals!

Arrowhead Pharmaceuticals recently discussed its fiscal 2024 third-quarter performance and provided updates on its drug pipeline and commercial...

Baptista Research

Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas!

Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)